List of works - Zachary A. Cooper

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

scientific article published in February 2018

Acetylation Directs Survivin Nuclear Localization to Repress STAT3 Oncogenic Activity ⬇️

scientific article published on September 8, 2010

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

scientific article

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

scientific article published on 14 June 2016

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

scientific article published on 15 June 2022

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

scientific article published on 10 January 2013

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

scientific article published on 15 October 2013

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics

scientific article

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial

scientific article published on 28 April 2016

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

article

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.

scientific article published on May 2013

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma

scientific article

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

scientific article published on 8 August 2017

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

scientific article published on 01 May 2020

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

scientific article published on 01 November 2018

Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma

scientific article published on 10 May 2016

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

scientific article published on 2 February 2016

Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy

scientific article published on 29 May 2015

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.

scientific article

EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells.

scientific article

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation

scientific article

Elucidating distinct roles for NF1 in melanomagenesis

scientific article

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

scientific article published on October 2014

Febrile range temperature represses TNF-alpha gene expression in LPS-stimulated macrophages by selectively blocking recruitment of Sp1 to the TNF-alpha promoter

scientific article published on 10 March 2010

Febrile-range temperature modifies cytokine gene expression in LPS-stimulated macrophages by differentially modifying NF-{kappa}B recruitment to cytokine gene promoters

scientific article

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

scientific article

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

scientific article published on 2 November 2017

Heat shock co-activates interleukin-8 transcription.

scientific article

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

scientific article published on 08 October 2013

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma

scientific article published on 25 July 2016

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy

scientific article

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

scientific article published on March 2016

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma

scientific article published on 8 October 2014

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

scientific article

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

scientific article (publication date: 2015)

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

scientific article published on 8 December 2015

Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

scientific article published on 11 September 2020

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

scientific article

Novel Treatments in Development for Melanoma.

scientific article

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

scientific article

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

scientific article

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

scientific article published on September 2017

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma

Raising the bar: optimizing combinations of targeted therapy and immunotherapy

scientific article published on October 2015

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

scientific article

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

scientific article published on 01 October 2020

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

scientific article published on 15 April 2020

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

scientific article

Targeted Therapies Combined With Immune Checkpoint Therapy.

scientific article published on March 2016

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

scientific article published on 12 June 2017

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

scientific article published on 09 February 2015

The human tumor microbiome is composed of tumor type-specific intracellular bacteria

scientific article

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα

scientific article

Toll-like receptor agonists and febrile range hyperthermia synergize to induce heat shock protein 70 expression and extracellular release.

scientific article published on 4 December 2012

Universes collide: combining immunotherapy with targeted therapy for cancer

scientific article

Working with Human Tissues for Translational Cancer Research.

scientific article published on 26 November 2015

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

scientific article published on 4 April 2016

List of works by Zachary A. Cooper

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Acetylation Directs Survivin Nuclear Localization to Repress STAT3 Oncogenic Activity ⬇️

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.

EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells.

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation

Elucidating distinct roles for NF1 in melanomagenesis

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

Febrile range temperature represses TNF-alpha gene expression in LPS-stimulated macrophages by selectively blocking recruitment of Sp1 to the TNF-alpha promoter

Febrile-range temperature modifies cytokine gene expression in LPS-stimulated macrophages by differentially modifying NF-{kappa}B recruitment to cytokine gene promoters

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Heat shock co-activates interleukin-8 transcription.

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Novel Treatments in Development for Melanoma.

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma

Raising the bar: optimizing combinations of targeted therapy and immunotherapy

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Targeted Therapies Combined With Immune Checkpoint Therapy.

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

The human tumor microbiome is composed of tumor type-specific intracellular bacteria

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα

Toll-like receptor agonists and febrile range hyperthermia synergize to induce heat shock protein 70 expression and extracellular release.

Universes collide: combining immunotherapy with targeted therapy for cancer

Working with Human Tissues for Translational Cancer Research.

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance